SAN DIEGO, March 5 Ardea Biosciences, Inc.(Nasdaq: RDEA) today announced the relocation of the Company's corporateheadquarters and research laboratories to San Diego. The new facility will bein the Sorrento Valley and will house the Company's research, preclinical andclinical development, pharmaceutical sciences and administrative operations.
"Moving our two southern California facilities to San Diego'sbiotechnology corridor is integral to our future growth and success, unitingthe organization while providing access to a wealth of biotechnology andpharmaceutical industry expertise," said Barry D. Quart, PharmD, ArdeaBiosciences' President and CEO. "We look forward to becoming an importantcontributor to the San Diego community at large."
Employees from both southern California locations will be relocating toour new facility and additional career opportunities can be found on the"Careers" page of the Company's website at http://www.ardeabio.com. Foradditional career related information please email [email protected]
About Ardea Biosciences, Inc.
Ardea Biosciences of San Diego, California is a biotechnology companyfocused on the discovery and development of small-molecule therapeutics invirology, oncology and inflammation. The Company has two product candidatesin clinical development and several others in preclinical development.Ardea's most advanced clinical development candidate is RDEA806, anon-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2astudy for the treatment of HIV. In addition, the Company is investigatingRDEA806 for the treatment of gout. The Company's lead mitogen-activated ERKkinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancerpatients and is being investigated for the treatment of inflammatory diseases.Ardea also is developing a next-generation NNRTI for HIV and a next-generationMEK inhibitor for both cancer and inflammatory diseases.
Statements contained in this press release regarding matters that are nothistorical facts are "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995. Because such statements aresubject to risks and uncertainties, actual results may differ materially fromthose expressed or implied by such forward-looking statements. Suchstatements include, but are not limited to, statements regarding: Ardea'sgoals, including the expected properties and benefits of RDEA806 and RDEA119and its other compounds and the results of clinical and other studies. Risksthat contribute to the uncertain nature of the forward-looking statementsinclude: risks related to the outcomes of preclinical and clinical studies,risks related to regulatory approvals, delays in commencement of preclinicaland clinical studies, and costs associated with internal development andin-licensing activities. These and other risks and uncertainties aredescribed more fully in Ardea's most recently filed SEC documents, includingits Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under theheadings "Risk Factors." All forward-looking statements contained in thispress release speak only as of the date on which they were made. Ardeaundertakes no obligation to update such statements to reflect events thatoccur or circumstances that exist after the date on which they were made.New Contact Information as of March 4, 2008: Ardea Biosciences, Inc. 4939 Directors Place San Diego, CA 92121 Telephone: 858-652-6500 Fax: 858-625-0760
SOURCE Ardea Biosciences, Inc.